The magnitude and characteristics of the population of cancer survivors: using population-based estimates of cancer prevalence to inform service planning for survivorship care

BMC Cancer

Linda Sharp³  Sandra Deady³  Pamela Gallagher²  Michal Molcho¹  Alison Pearce³  Audrey Alforque Thomas¹  Aileen Timmons³  Harry Comber³ 

[1] National University of Ireland, Galway, Ireland

[2] Dublin City University, Dublin, Ireland

[3] National Cancer Registry, Building 6800, Cork Airport Business Park, Kinsale Road, Cork, Ireland

关键词: Unmet needs;    Supportive care;    Survivors;    Prevalence;    Cancer;   

Others  :  1120973
DOI  :  10.1186/1471-2407-14-767

 received in 2014-01-27, accepted in 2014-09-24,  发布年份 2014

【 摘 要 】

Background

Rising cancer incidence and survival mean that the number of cancer survivors is growing. Accumulating evidence suggests many survivors have long-term medical and supportive care needs, and that these needs vary by survivors’ socio-demographic and clinical characteristics. To illustrate how cancer registry data may be useful in survivorship care service planning, we generated population-based estimates of cancer prevalence in Ireland and described socio-demographic and clinical characteristics of the survivor population.

Methods

Details of people diagnosed with invasive cancer (ICD10 C00-C96) during 1994–2011, and who were still alive on 31/12/2011, were abstracted from the National Cancer Registry, and tabulated by cancer site, sex, current age, marital status, initial treatment, and time since diagnosis. Associations were investigated using chi-square tests.

Results

After excluding non-melanoma skin cancers, 17-year cancer prevalence in Ireland was 112,610 (females: 58,054 (52%) males: 54,556 (48%)). The four most prevalent cancers among females were breast (26,066), colorectum (6,598), melanoma (4,593) and uterus (3,505) and among males were prostate (23,966), colorectum (8,207), lymphoma (3,236) and melanoma (2,774). At the end of 2011, 39% of female survivors were aged <60 and 35% were ≥70 compared to 25% and 46% of males (p < 0.001). More than half of survivors of bladder, colorectal and prostate cancer were ≥70. Cancers with the highest percentages of younger (<40) survivors were: testis (50%); leukaemia (females: 28%; males: 22%); cervix (20%); and lymphoma (females: 19%; males: 20%). Fewer female (57%) than male (64%) survivors were married but the percentage single was similar (17-18%). More female (25%) than male survivors (18%; p < 0.001) were ≥10 years from diagnosis. Overall, 69% of survivors had undergone cancer-directed surgery, and 39%, 32% and 18% had received radiotherapy, chemotherapy and hormone therapy, respectively. These frequencies were higher among females than males (surgery: 82%, 54%; radiotherapy: 42%, 35%; chemotherapy: 40%, 22%; hormone therapy: 23%, 13%).

Conclusions

These results reveal the socio-demographic and clinical heterogeneity of the survivor population, and highlight groups which may have specific medical and supportive care needs. These types of population-based estimates may help decision-makers, planners and service providers to develop follow-up and after-care services to effectively meet survivors’ needs.

【 授权许可】

   
2014 Sharp et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
• [2]Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49:1374-1403.
• [3]Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Allemani C, Tavilla A, Santaquilani M, Sant M, EUROCARE Working Group: Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 2009, 45:1042-1066.
• [4]National Cancer Registry: Cancer in Ireland 2013. Annual Report of the National Cancer Registry. Cork: National Cancer Registry; 2013.
• [5]Macmillan Cancer Support: Two million reasons. The cancer survivorship agenda. London: Macmillan Cancer Support; 2008.
• [6]Hewitt M, Greenfield S, Stovall E (Eds): From cancer patient to cancer survivor. Lost in transition. Washington DC: The National Academies Press; 2005.
• [7]Galbraith ME, Hays L, Tanner T: What men say about surviving prostate cancer: complexities represented in a decade of comments. Clin J Oncol Nurs 2012, 16:65-72.
• [8]Sandsund C, Pattison N, Doyle N, Shaw C: Finding a new normal: a grounded theory study of rehabilitation after treatment for upper gastrointestinal or gynaecological cancers-the patient’s perspective. Eur J Cancer Care (Engl) 2013, 22:232-244.
• [9]Sherman DW, Rosedale M, Haber J: Reclaiming life on one’s own terms: a grounded theory study of the process of breast cancer survivorship. Oncol Nurs Forum 2012, 39:E258-E268.
• [10]Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW: Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 2005, 55:231-240.
• [11]Kalam K, Marwick TH: Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 2013, 49:2900-2909.
• [12]Raj KA, Marks LB, Prosnitz RG: Late effects of breast radiotherapy in young women. Breast Dis 2005, 23:53-65.
• [13]Miller MP, Stanley TV: Results of a mass screening program for colorectal cancer. Arch Surg 1988, 123:63-65.
• [14]Keating NL, O’Malley A, Freedland SJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2012, 104:1518-1523.
• [15]Sioka C, Kyritsis AP: Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 2009, 63:761-767.
• [16]Valdivieso M, Kujawa AM, Jones T, Baker LH: Cancer survivors in the United States: a review of the literature and a call to action. Int J Med Sci 2012, 9:163-173.
• [17]Corner J: Addressing the needs of cancer survivors: issues and challenges. Expert Rev Pharmacoecon Outcomes Res 2008, 8:443-451.
• [18]Newell S, Sanson-Fisher RW, Girgis A, Ackland S: The physical and psycho-social experiences of patients attending an outpatient medical oncology department: a cross-sectional study. Eur J Cancer Care 1999, 8:73-82.
• [19]Smith DP, Supramaniam R, King MT, Ward J, Berry M, Armstrong BK: Age, health, and education determine supportive care needs of men younger than 70 years with prostate cancer. J Clin Oncol 2007, 25:2560-2566.
• [20]Ream E, Quennell A, Fincham L, Faithfull S, Khoo V, Wilson-Barnett J, Richardson A: Supportive care needs of men living with prostate cancer in England: s survey. Br J Cancer 2008, 98:1903-1909.
• [21]Harrison JD, Young JM, Price MA, Butow PN, Solomon MJ: What are the unmet supportive care needs of people with cancer? A systematic review. Support Care Cancer 2009, 17:1117-1128.
• [22]Krouse RS, Herrinton LJ, Grant M, Wendel CS, Green SB, Mohler MJ, Baldwin CM, McMullen CK, Rawl SM, Matayoshi E, Coons SJ, Hornbrook MC: Health-related quality of life among long-term rectal cancer survivors with an ostomy: manifestations by sex. J Clin Oncol 2009, 27:4664-4670.
• [23]Puts MT, Papoutsis A, Springall E, Tourangeau AE: A systematic review of unmet needs of newly diagnosed older cancer patients undergoing active cancer treatment. Support Care Cancer 2012, 20:1377-1394.
• [24]Giles G: How important are estimates of cancer prevalence? Ann Oncol 2002, 13:815-816.
• [25]Bastos J, Peleteiro B, Gouveia J, Coleman MP, Lunet N: The state of the art of cancer control in 30 European countries in 2008. Int J Cancer 2010, 126:2700-2715.
• [26]Parkin DM: The evolution of the population-based cancer registry. Nat Rev Cancer 2006, 6:603-612.
• [27]Brewster DH, Coebergh JW, Storm HH: Population-based cancer registries: the invisible key to cancer control. Lancet Oncol 2005, 6:193-195.
• [28]O’Brien K, Comber H, Sharp L: Completeness of case ascertainment at the Irish National Cancer Registry. Ir J Med Sci 2014, 183:219-24.
• [29]Bray F, Ren JS, Masuyer E, Ferlay J: Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013, 132(5):1133-1145.
• [30]N. Ireland Cancer Registry: Living with and beyond cancer. A report on cancer prevalence in Northern Ireland 2010. Belfast: N. Ireland Cancer Registry; 2013.
• [31]Herrmann C, Cerny T, Savidan A, Vounatsou P, Konzelmann I, Bouchardy C, Frick H, Ess S: Cancer survivors in Switzerland: a rapidly growing population to care for. BMC Cancer 2013, 13:287-2407. 3-287 BioMed Central Full Text
• [32]De Angelis R, Grande E, Inghelmann R, Francisci S, Micheli A, Baili P, Meneghini E, Capocaccia R, Verdecchia A: Cancer prevalence estimates in Italy from 1970 to 2010. Tumori 2007, 93:392-397.
• [33]Maddams J, Brewster D, Gavin A, Steward J, Elliott J, Utley M, Møller H: Cancer prevalence in the United Kingdom: estimates for 2008. Br J Cancer 2009, 101:541-547.
• [34]Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012, 62:220-241.
• [35]Maher J, McConnell H: New pathways of care for cancer survivors: adding the numbers. Br J Cancer 2011, 105:S5-S10.
• [36]Mitchell AJ, Ferguson DA, Gill J, Paul J, Symonds P: Depression and anxiety in long-term survvors compared to spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol 2013, 14:721-732.
• [37]Li WW, Lam WW, Au AH, Ye M, Law WL, Poon J, Kwong A, Suen D, Tsang J, Girgis A, Fielding R: Interpreting differences in patterns of supportive care needs between patients with breast cancer and patients with colorectal cancer. Psychooncology 2013, 22:792-798.
• [38]Smith A, King M, Butow P, Luckett T, Grimison P, Toner GC, Stockler M, Hovey E, Stubbs J, Hruby G, Gurney H, Turner S, Alam M, Cox K, Olver I: The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. Psychooncology 2013, 22:2557-2564.
• [39]Timmons A, Gooberman-Hill R, Sharp L: “It’s a time in your life when you are most vulnerable”: a qualitative exploration of the financial impact of a cancer diagnosis and implications for financial protection in health. PLoS One 2013, 8:1-11.
• [40]Parry C, Kent EE, Mariotto AB, Alfano CM, Rowland JH: Cancer survivors: a booming population. Cancer Epidemiol Biomarkers Prev 2011, 20:1996-2005.
• [41]Deimling GT, Kahana B, Bowman KF, Schaefer ML: Cancer survivorship and psychological distress in later life. Psycho-oncol 2002, 11:479-494.
• [42]Bellury L, Pett MA, Ellington L, Beck SL, Clark JC, Stein KD: The effect of ageing and cancer on the symptom experience and physical function of elderly breast cancer survivors. Cancer 2012, 118:6171-6178.
• [43]Bennett JA, Winters-Stone KM, Dobek J, Nail JM: Frailty in older breast cancer survivors: age, prevalence, and associated factors. Oncol Nurs Forum 2013, 40:E126-E134.
• [44]Vrov EK, Fossa SD, Dahl AA: Is somatic comorbidity associated with more somatic symptoms, mental distress, or unhealthy lifestyle in elderly cancer survivors. J Cancer Surviv 2009, 3:109-116.
• [45]Moore S, Corner J, Haviland J, Wells M, Salmon E, Normand C, Brada M, O’Brien M, Smith I: Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial. BMJ 2002, 325:1145-1151.
• [46]Wattchow DA, Weler DA, Esterman A, Pilotto LS, McGorm K, Hammett Z, Platell C, Silagy C: General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial. Br J Cancer 2006, 94:1116-1121.
• [47]Central Statistics Office: Survey on Income and Living Conditions (SILC) Thematic Report on the Elderly, 2004, 2009 and 2010. Available at URL: http://www.cso.ie/en/media/csoie/releasespublications/documents/silc/2010/elderly/0409and10.pdf webcite [Accessed 28th October 2014]
• [48]Raine R, Wong W, Scholes S, Ashton C, Obichere A, Ambler G: Social variations in access to hospital care for patients with colorectal, breast, and lung cancer between 1999 and 2006: retrospective analysis of hospital episode statistics. BMJ 2010, 340:b5479.
• [49]Forrest LF, Adams J, Wareham H, Rubin G, White M: Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis. PLoS Med 2013, 10:e1001376.
• [50]Mohd Noor A, Sarker D, Vizor S, McLennan S, Hunter S, Suder A, Moller H, Spicer JF, Papa S: Effect of patient socioeconomic status on access to early-phase cancer trials. J Clin Oncol 2013, 31:224-230.
• [51]Paterson HM, Mander BJ, Muir P, Phillips HA, Wild SH: Deprivation and access to treatment for colorectal cancer in Southeast Scotland 2003–2009. Colorectal Dis 2014, 16:O51-7.
• [52]Vivar CG, McQueen A: Informational and emotional needs of long-terms survivors of breast cancer. J Adv Nurs 2005, 51:520-528.
• [53]Hodgkinson K, Butow P, Hunt GE, Pendlebury S, Hobbs KM, Wain G: Breast cancer survivors’ supportive care needs 2–10 years after diagnosis. Support Cancer Care 2007, 15:515-523.
• [54]Ferlay J:P,DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781.
• [55]Carsin AE, Drummond FJ, Black A, van Leeuwen PJ, Sharp L, Murray LJ, Connolly D, Egevad L, Boniol M, Autier P, Comber H, Gavin A: Impact of PSA testing and prostatic biopsy on cancer incidence and mortality: comparative study between the Republic of Ireland and Northern Ireland. Cancer Causes Control 2010, 21:1523-1531.
• [56]Gomella LG, Johannes J, Trabulsi EJ: Current prostate cancer treatments: effect on quality of life. Urology 2009, 73:S28-S35.
• [57]Kinnear H, Drummond F, Sharp L, Gavin A: An all-Ireland population-based study of past and current physical and psychological side-effects following prostate cancer. J Clin Urol 2013, 6:337-345.
• [58]Gail MH, Kessler L, Midthune D, Scoppa S: Two approaches for estimating disease prevalence from population-based registries of incidence and total mortality. Biometrics 1999, 55:1137-1144.
• [59]Mallone S, De Angelis R, van der Zwan JM, Trama A, Siesling S, Gatta G, Capocaccia R, The RARECARE WG: Methodological aspects of estimating rare cancer prevalence in Europe: The experience of the RARECARE project. Cancer Epidemiol 2013, 37:850-6.
• [60]Aarts MJ, Mols F, Thong MS, Louwman MW, Coebergh JW, van der Poll-Franse LV: Long-term prostate cancer survivors with low socio-economic status reported worse mental health-related quality of life in a population-based study. Urology 2010, 76:1224-1230.
• [61]Butow PN, Aldridge L, Bell ML, Sze M, Eisenbruch M, Jefford M, Schofiel P, Girgis A, King M, Duggal-Beri P, McGrane J, Goldstein D: Inferior health-related quality-of-life and psychological well-being in immigrant cancer survivors: a population-based study. Eur J Cancer 2013, 49:1948-1956.
• [62]Shin HW, Noh DY, Lee ES, Nam SJ, Park BW, Ahn SH, Yun YH: Correlates of existential well-being and their association with health-related quality of life in breast cancer survivors compared to the general population. Breast Cancer Res Treat 2009, 118:139-150.
• [63]Thomas AA, Timmons A, Molcho M, Pearce A, Gallagher P, Butow P, O’Sullivan E, Gooberman-Hill R, O’Neill C, Sharp L: Quality of Llfe in urban and rural settings: a study of head and neck cancer survivors. Oral Oncol 2014, 50:676-682.
• [64]Thomas AA, Gallagher P, O’Ceilleachair A, Pearce A, Sharp L, Molcho M: Distance from treating hospital and colorectal cancer survivors’ quality of life: a gendered analysis. Support Care Cancerin press
• [65]National Cancer Registry: Cancer projections for Ireland 2015–2040. Cork: National Cancer Registry; 2014.